乙卡氟特 | 65400-85-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 乙卡氟特
• 中文别名: 卡氟卓乙酯
• 英文名称: 7-chloro-5-(2-fluoro-phenyl)-1-methylcarbamoyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepine-3-carboxylic acid ethyl ester
• 英文别名: Ethyl carfluzepate；ethyl 7-chloro-5-(2-fluorophenyl)-1-(methylcarbamoyl)-2-oxo-3H-1,4-benzodiazepine-3-carboxylate
• CAS: 65400-85-3
• 化学式: C₂₀H₁₇ClFN₃O₄
• 分子量: 417.824
• InChiKey: PUJLIQLPZOZCOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  88.1
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• CD38-BINDING CD31 PEPTIDES AND USES THEREOF
  申请人：ENCEFA

  公开号：EP3943505A1

  公开（公告）日：2022-01-26

  The present invention relates to peptides derived from CD31, specifically binding to CD38; and their use in the prevention and/or treatment of diseases.

  本发明涉及从 CD31 衍生的肽，特别是与 CD38 结合的肽；以及它们在预防和/或治疗疾病中的用途。
• Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
  申请人：Hsu John

  公开号：US10004749B2

  公开（公告）日：2018-06-26

  The present disclosure provides a safe method for anesthesia or the treatment of pain by safely administering an amount of active agent to a patient while reducing the incidence or severity of suppressed respiration. The present disclosure provides a pharmaceutical composition comprising a therapeutic agent and a chemoreceptor respiratory stimulant. In one aspect, the compositions oppose effects of respiratory suppressants by combining a chemoreceptor respiratory stimulant with an opioid receptor agonist or other respiratory-depressing drug. The combination of the two chemical agents, that is, the therapeutic agent and the respiratory stimulant, may be herein described as the “drugs.” The present compositions may be used to treat acute and chronic pain, sleep apnea, and other conditions, leaving only non-lethal side effects.

  本公开提供了一种安全的麻醉或疼痛治疗方法，通过安全地向患者施用一定量的活性剂，同时降低呼吸抑制的发生率或严重程度。本公开提供了一种药物组合物，它包含一种治疗剂和一种化学感受器呼吸兴奋剂。在一个方面，该组合物通过将化学感受器呼吸兴奋剂与阿片受体激动剂或其他呼吸抑制药物相结合来对抗呼吸抑制剂的作用。两种化学制剂的组合，即治疗剂和呼吸兴奋剂，在此可称为 "药物"。本组合物可用于治疗急性和慢性疼痛、睡眠呼吸暂停和其他病症，只留下不致命的副作用。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• Topical pharmaceutical composition containing phenytoin and a (co-) analgesic for the treatment of chronic pain
  申请人：Topical Innovations B.V.

  公开号：US11147799B2

  公开（公告）日：2021-10-19

  This disclosure relates to a pharmaceutical composition for topical use wherein the active pharmaceutical ingredient consists of the co-analgesic phenytoin and at least one further co-analgesic, and a method for producing the pharmaceutical composition. In addition, the disclosure relates to the pharmaceutical composition for use in the treatment of chronic pain.

  本公开涉及一种局部使用的药物组合物，其中的活性药物成分包括共镇痛剂苯妥英和至少另一种共镇痛剂，还涉及一种生产该药物组合物的方法。此外，本发明还涉及用于治疗慢性疼痛的药物组合物。